Download Social Media Radar Here!
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Templeton Eafe Developed Markets Fund
TEMPLETON EAFE As at September 30, 2020 DEVELOPED MARKETS FUND Summary of Investment Portfolio REGIONAL WEIGHTINGS (%)* ASSET CLASS WEIGHTINGS (%) Europe 49.97 Common Stocks 91.84 Asia 41.87 Short-term securities and all other assets, net 8.16 INDUSTRY WEIGHTINGS (%)* TOP 25 HOLDINGS (%) Pharmaceuticals 10.94 Cash and cash equivalents** 5.79 Electronic Equipment, Instruments & Components 5.49 Deutsche Telekom AG 3.39 Multi-Utilities 5.30 Takeda Pharmaceutical Co. Ltd. 3.11 Real Estate Management & Development 5.05 E.ON SE 2.95 Chemicals 4.71 Hitachi Ltd. 2.93 Food & Staples Retailing 4.23 Fresenius Medical Care AG & Co. KGaA 2.83 Banks 4.18 BAE Systems PLC 2.80 Automobiles 4.09 AIA Group Ltd. 2.72 Semiconductors & Semiconductor Equipment 3.99 Bayer AG 2.63 Diversified Telecommunication Services 3.47 Kyocera Corp. 2.55 Oil, Gas & Consumable Fuels 2.96 Sumitomo Metal Mining Co. Ltd. 2.48 Health Care Providers & Services 2.83 Honda Motor Co. Ltd. 2.41 Aerospace & Defense 2.80 Sony Corp. 2.37 Textiles, Apparel & Luxury Goods 2.74 Covestro AG 2.36 Insurance 2.72 NXP Semiconductors NV 2.36 Machinery 2.60 Veolia Environnement SA 2.35 Metals & Mining 2.48 Matsumotokiyoshi Holdings Co. Ltd. 2.22 Wireless Telecommunication Services 2.44 Komatsu Ltd. 2.18 Industrial Conglomerates 2.38 Mitsui Fudosan Co. Ltd. 2.13 Household Durables 2.37 Roche Holding AG 2.08 Electrical Equipment 1.80 Sanofi 2.05 Construction & Engineering 1.59 Seven & i Holdings Co. Ltd. 2.01 Construction Materials 1.57 Sumitomo Mitsui Financial Group Inc. -
The United States District Court for the Southern. District of Florida
UNITEDBTATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA ADMINISTRATIVE ORDER 2021-46 INRE: ·FILED BY CW D.C. EXEMPTION OF FEES TO ACCESS PACER May 20, 2021 FOR EMILY M. HOMER. ANGE\.AI:. NOBl..E Cl.ERKU.S. CIST..C'i'. S. 0. OF Fl.A - MIA The United States District Court for the Southern.District of Florida maintains case information online with the Public Access to Court Electronic Records (PACER) website. The Court desires to encourage the public's use of the database and to· continue to promote public access and to avoid unreasonable burdens on both users and court staffin retrievmg data. The Court finds that Emily M. Homer, as an individual researcher associated with an educationalinstitution, falls within the class of users listed in thefee schedule as being eligible for a fee exemption. Additionally, Ms. Homer has demonstrated that an exemption is necessary in order to avoid unreasonable burdens and to promote public access to information. It is hereby ORDERED AND ADJUDGED that Emily M. Homer shall be exempt from the . payment of fees for access via PACER to the electronic case files maintained in this Court, to the extent such use is incurred in the course of her research, specifically an examination of corporate deterrence and recidivism in 174 public organizations listed on Appendix 1 that signed deferred prosecution and non-prosecution agreements with federal prosecutors between 1992-2020. Ms. Homer will use this information to determine the frequency of violations to gauge the effectiveness of corporate agreements in preventing recidivism. Ms. Homer shall not be exempt from the payment of fees incurred in connection with other · uses of the PACER system in this Court. -
Cboe Germany 30 Index BDE30P
Cboe Germany 30 Index BDE30P Page 1 August 2021 Cboe Exchange The Cboe DE 30 index aims to be comprised of the largest 30 German issuers. This is a price return index. Objective The index is designed for use in the creation of index tracking funds, derivatives and as a performance benchmark. Investability Liquidity Transparency Availability Stocks are selected and Stocks are screened to Uses a transparent, rules-based Calculation is based on weighted to ensure that the ensure that the index is construction process. Index price and total return index is investable. tradable. Rules are freely available on the methodologies, both real cboe.com/europe/indices -time, intra-second and website. end of day. Statistics Index ISIN Ticker RIC Currency Cboe Germany 30 DE000SLA2P95 BDE30P .BDE30P EUR Cboe Germany 30 - net DE000SLA2QH0 BDE30N .BDE30N EUR Volatility Volatility (1y) 0.1741 Returns(%) 1M 3M 6M YTD 1Y 3Y 5Y BDE30P 1.81 2.58 11.45 11.58 17.02 13.3 24.82 BDE30N 1.81 2.65 13.3 13.68 19.32 21.0 38.83 Top 5 Performers Country 1 month return % MERCK KGAA GERMANY 17.08 INFINEON TECHNOLOGIES AG GERMANY 11.63 RWE AG GERMANY 10.07 HANNOVER RUCK SE GERMANY 9.68 MUNICH REINSURANCE COMPANY GERMANY 8.34 Historical Performance Chart 250% 200% 150% 100% 50% 0% 2011 2013 2014 2016 2017 2018 2020 2021 Cboe Germany 30 (EUR) Cboe Germany Mid Cap 50 (EUR) Cboe Germany Small Cap 50 (EUR) Cboe.com | ©Cboe | /CboeGlobalMarkets | /company/cboe © 2021 Cboe Exchange, Inc. All Rights Reserved. -
Eurozone 120, Euronext Vigeo US 50, Euronext Vigeo France 20, Euronext Vigeo United Kingdom 20 and Euronext Vigeo Benelux 20, Will Be Updated Every Six Months
Vigeo Eiris’ indices are composed of the highest-ranking listed companies as evaluated by the agency in terms of their performance in corporate responsibility. This range of indices: Euronext Vigeo World 120, Euronext Vigeo Europe 120, Euronext Vigeo Eurozone 120, Euronext Vigeo US 50, Euronext Vigeo France 20, Euronext Vigeo United Kingdom 20 and Euronext Vigeo Benelux 20, will be updated every six months. Constituent selection is based on data from the Equitics® methodology, developed by Vigeo. Selected companies have achieved the highest ratings in their reference universe. INDEX FEATURES Number of Constituents 120 Index Type Price Index Eligible Stock All the companies included in the related Vigeo Euronext Universe The weighting of each component at the review date reflects the Equitics® score of the Weighting company divided by the total sum of the scores of all components Review Semi-Annually ( June and December) New constituents – November 2016 Eurozone 120: the 4 most A2A Electric & Gas Utilities ABN-AMRO Hldg Diversified Banks represented sectors Carrefour Supermarkets Covestro AG Chemicals Enagas Electric & Gas Utilities 13% Fortum Electric & Gas Utilities Electric & Gas Utilities Groupe Casino Supermarkets 9% Chemicals HEIDELBERG CEMENT AG Building Materials Jerónimo Martins Supermarkets Diversified Publicis Groupe Broadcasting & Advertising 9% Banks Snam Electric & Gas Utilities Insurance 5% WARTSILA Industrial Goods & Services Other Information on performance Average overall score 55/100 Lowest global score 46/100 Highest -
Portfolio of Investments
PORTFOLIO OF INVESTMENTS CTIVP® – Lazard International Equity Advantage Fund, September 30, 2020 (Unaudited) (Percentages represent value of investments compared to net assets) Investments in securities Common Stocks 97.6% Common Stocks (continued) Issuer Shares Value ($) Issuer Shares Value ($) Australia 6.9% Finland 1.0% AGL Energy Ltd. 437,255 4,269,500 Metso OYJ 153,708 2,078,669 ASX Ltd. 80,181 4,687,834 UPM-Kymmene OYJ 36,364 1,106,808 BHP Group Ltd. 349,229 9,021,842 Valmet OYJ 469,080 11,570,861 Breville Group Ltd. 153,867 2,792,438 Total 14,756,338 Charter Hall Group 424,482 3,808,865 France 9.5% CSL Ltd. 21,611 4,464,114 Air Liquide SA 47,014 7,452,175 Data#3 Ltd. 392,648 1,866,463 Capgemini SE 88,945 11,411,232 Fortescue Metals Group Ltd. 2,622,808 30,812,817 Cie de Saint-Gobain(a) 595,105 24,927,266 IGO Ltd. 596,008 1,796,212 Cie Generale des Etablissements Michelin CSA 24,191 2,596,845 Ingenia Communities Group 665,283 2,191,435 Electricite de France SA 417,761 4,413,001 Kogan.com Ltd. 138,444 2,021,176 Elis SA(a) 76,713 968,415 Netwealth Group Ltd. 477,201 5,254,788 Legrand SA 22,398 1,783,985 Omni Bridgeway Ltd. 435,744 1,234,193 L’Oreal SA 119,452 38,873,153 REA Group Ltd. 23,810 1,895,961 Orange SA 298,281 3,106,763 Regis Resources Ltd. -
ASN Kidney Week 2020 Reimagined: Disclosures Page 1
10/14/2020 ASN Kidney Week 2020 Reimagined: Disclosures Page 1 Last Name First Name Nothing Employer Consultancy Ownership Interest Research Funding Honoraria Patents or Inventions Scientific Advisor or Membership Speakers Bureau Other Interests or Relationships to Disclose Abdel-Kader Khaled Vanderbilt University Medical Center BMC Nephrology; CJASN NKF Education committee; NIDDK Health IT work group Abudayyeh Ala University of Texas MD Anderson Cancer Center Adler Sharon Retrophin; Bristol Myers Squibb; Bayer; Retrophin; Bayer; ChemoCentryx; Omeros; Zyversa Bayer; Zyversa; Retrophin; AstraZeneca; Morphosys Retrophin; Bayer Pharmaceuticals; Zyversa; KDIGO; KRN; NephCure Kidney International AstraZeneca; ChemoCentryx; Omeros; Zyversa; Therapeutics; Calliditas; Morphosys AstraZeneca; Morphosys Foundation; Karger Publishers Morphosys; Karger Afkarian Maryam University of California, Davis Afrouzian Marjan University of Texas Medical Branch Alexion Pharmaceuticals; Banff Foundation Afshinnia Farsad Agarwal Anupam University of Alabama at Birmingham Dynamed - review content related to AKI for Goldilocks Therapeutics Genzyme/Sanofi Fabry Fellowship Award Univ Southern California, Vanderbilt, Emory, Akebia Editorial Board of AJP Renal, Kidney Int and My wife, Lisa Curtis, will be President-elect Dynamed and review updated materials prepared by Lab Investigation; invited to serve on for Women in Nephrology (2018-2019). Dynamed editorial team for AKI topics. Akebia - Advisory board of Goldilocks Therapeutics, Expert Panel to review new therapeutics -
Euro Stoxx® International Exposure Index
EURO STOXX® INTERNATIONAL EXPOSURE INDEX Components1 Company Supersector Country Weight (%) ASML HLDG Technology Netherlands 6.02 LVMH MOET HENNESSY Consumer Products & Services France 4.99 LINDE Chemicals Germany 3.79 SAP Technology Germany 3.62 SANOFI Health Care France 3.20 IBERDROLA Utilities Spain 3.04 SIEMENS Industrial Goods & Services Germany 2.63 AIR LIQUIDE Chemicals France 2.17 SCHNEIDER ELECTRIC Industrial Goods & Services France 2.10 L'OREAL Consumer Products & Services France 2.05 ANHEUSER-BUSCH INBEV Food, Beverage & Tobacco Belgium 1.99 BASF Chemicals Germany 1.89 ADIDAS Consumer Products & Services Germany 1.76 AIRBUS Industrial Goods & Services France 1.68 DAIMLER Automobiles & Parts Germany 1.65 BAYER Health Care Germany 1.61 PHILIPS Health Care Netherlands 1.51 ADYEN Industrial Goods & Services Netherlands 1.49 ESSILORLUXOTTICA Health Care France 1.40 DEUTSCHE TELEKOM Telecommunications Germany 1.36 INFINEON TECHNOLOGIES Technology Germany 1.35 Kering Retail France 1.35 BCO SANTANDER Banks Spain 1.29 SAFRAN Industrial Goods & Services France 1.26 HERMES INTERNATIONAL Consumer Products & Services France 1.10 PERNOD RICARD Food, Beverage & Tobacco France 1.09 CRH Construction & Materials Ireland 1.09 DEUTSCHE POST Industrial Goods & Services Germany 1.05 BCO BILBAO VIZCAYA ARGENTARIA Banks Spain 1.03 FLUTTER ENTERTAINMENT Travel & Leisure Ireland 1.02 DANONE Food, Beverage & Tobacco France 1.00 MUENCHENER RUECK Insurance Germany 0.99 VOLKSWAGEN PREF Automobiles & Parts Germany 0.82 BMW Automobiles & Parts Germany 0.80 -
Bayer AG Financial Statements 2015 2 Bayer AG Financial Statements 2015 Contents
Bayer AG Financial Statements 2015 2 Bayer AG Financial Statements 2015 Contents The management report of Bayer AG is combined with the management report of the Bayer Group. The Combined Management Report is published in Bayer’s Annual Report for 2015. The financial statements and the Combined Management Report of the Bayer Group and Bayer AG for fiscal 2015 have been submitted to the operator of the electronic Federal Gazette in Germany and are accessible via the Company Register website. Contents FINANCIAL STATEMENTS Income Statements 3 Statements of Financial Position 4 Notes to the Financial Statements 5 Accounting Policies 5 Recognition and Valuation Principles 5 Notes to the Income Statements 8 Notes to the Statements of Financial Position 13 Other Information 25 PROPOSAL FOR THE USE OF THE DISTRIBUTABLE PROFIT 47 RESPONSIBILITY STATEMENT 47 AUDITOR’S REPORT 48 FURTHER INFORMATION Governance Bodies 49 Financial Calendar, Masthead, Disclaimer 52 Bayer AG Financial Statements 2015 3 Income Statements Income Statements Note 2014 2015 € million € million Income from investments in affiliated companies – net [1] 3,213 2,444 Interest expense – net [2] (341) (484) Other financial income – net [3] 129 409 Other operating income [4] 128 99 General administration expenses (272) (324) Other operating expenses [5] (147) (177) Income before income taxes 2,710 1,967 Income taxes [6] (256) (606) Net income 2,454 1,361 Allocation to other retained earnings / Withdrawal from other retained earnings (593) 706 Distributable profit 1,861 2,067 4 Bayer -
2019 Spring Attendee List
2019 Spring Attendee List Allison Pauline 3M Clemens Tim 3M Koch Joseph 3M Selph Gary 3M - Industrial Adhesives and Tapes Division Fan Wayne 3M Company Albrecht Steve Adherent Laboratories, Inc. Meyer Paul Adherent Laboratories, Inc. Allmond Bill Adhesive and Sealant Council Armstrong Malinda Adhesive and Sealant Council Collatz Mark Adhesive and Sealant Council Duren Steve Adhesive and Sealant Council Howe Connie Adhesive and Sealant Council Mikharava Val Adhesive and Sealant Council Mittelstaedt Martha Adhesive and Sealant Council Nickoloff Myranda Adhesive and Sealant Council Shattuck Tim Adhesive Products, Inc. Shattuck Paul Adhesive Products, Inc. Vinuya Jeff Adhesive Products, Inc. Andrade Andrew Advanced Polymer, Inc. Mulcahy Christopher Advanced Polymer, Inc. Zhang Xiawei AdvanSix Nomuva Sadayuki AGC Chemicals Scott Jim AGC Chemicals Americas, Inc. Ushio Takaaki AGC Inc. Jeffries Gary Akrochem Corporation KING MARCIA Alberdingk Boley USA Vyas Ujjval Alberti Group, LLC Reynolds Robert Albion Engineering Company Schneider Mark Albion Engineering Company Slowinski Gene Alliance Management Group, Inc. Hutchins Marcus Allnex, USA Owings Lamar ALVAR, Inc. Shaw Jack American Blockchain Council Erchul Alex Andpak Midwest Mayes Chris Andpak Midwest Jobbins Matthew Anton PAAR USA Feriancek John Applied Adhesives Horner Dan Applied Adhesives, Inc. Webb Brian APPLIED Products, Inc. Osborne Greg Applied Test Systems Natushara Eisuke Arakawa Chemical (USA) Inc. Quenaud Bryan Arakawa Chemical (USA) Inc. Shen Calvin Aramco Performance Materials Chesson Mark Aramco Performance Materials LLC Suddaby Brian ARDEX Americas Lu Lida ARDEX Americas (W.W. Henry) Arendt William Arendt Consulting Niznik Paul Argus DeWitt Rogachevsky Vitaly Argus Media, Inc. Fortener Christine Arkema Drewery Michael Arkema Coating Resins Dumain Eric Arkema Coating Resins Mattern David Arkema Coating Resins Miner Rick Arkema Coating Resins Shulack Pat Arkema Coating Resins Yocca Kevin Arkema Coating Resins Donnelly Zuzanna Arkema Inc. -
SECURITIES and EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT of FOREIGN PRIVATE ISSUER PURSUANT to RULE 13A-16 OR
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ FRESENIUS MEDICAL CARE AG & Co. KGaA Interim Report of Financial Condition and Results of Operations for the three and six months ended June 30, 2021 and 2020 Page FINANCIAL INFORMATION Management’s discussion and analysis Forward-looking statements ..................................................................................................................................... 1 Financial condition and results of operations ........................................................................................................ 3 Overview ..................................................................................................................................................................... 3 Discussion of measures .......................................................................................................................................... -
Press Release: Fresenius Medical Care
Media Contact Michael Gavin T +49 6172 609-2978 [email protected] Press Release Media Contact for North America Brad Puffer T +1 781-699-3331 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] September 24, 2020 The Power of Ideas and the people behind them: Fresenius Medical Care publishes 2020 Global Annual Medical Report Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, today announced publication of its 2020 Global Annual Medical Report. Titled “The Power of Ideas: Ingenuity, Optimism, and the Future of Global Healthcare,” it advances the worldwide conversation about the continuing evolution of healthcare and underlines the role Fresenius Medical Care can play in transforming care for chronically ill patients. “This year’s report focuses on the ideas, ingenuity and optimism that are transforming healthcare,” said Franklin W. Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care. “We look at ways to enhance patient choice, new frontiers in connected health, the promise of artificial intelligence, and other important topics including our global response to COVID-19. Our 2020 report also shows the remarkable diversity of people behind the ideas that are helping us evolve our healthcare systems to recognize the unique lifetime journey of each kidney disease patient.” The 2020 Global Annual Medical Report comprises 24 chapters by nearly 40 authors from across the company, representing some of Fresenius Medical Care’s best thought leadership on a wide range of topics. -
From Good Intentions to Real Results – Corporate Citizenship of Germany's DAX 30 Companies
FROM GOOD INTENTIONS TO REAL RESULTS Corporate Citizenship of Germany’s DAX 30 Companies + Relevance: Why is Corporate Citizenship a CEO topic? + Trends: What are current and future expectations regarding Corporate Citizenship? + Current practice: How do DAX 30 companies engage in societal causes? + Good practices: What does good Corporate Citizenship look like? + Advice: How can you revise your own Corporate Citizenship approach? 03 01 EXECUTIVE CONTENTS SUMMARY 01 EXECUTIVE SUMMARY __ PAGE 03 We consider Corporate Citizenship as the contributions of businesses to society through the combination of core business activities, CORPORATE CITIZENSHIP social investment and philanthropy, and __ 02 IN A WORLD OF SOCIETAL CHALLENGES PAGE 06 participation in the public policy process. (World Economic Forum, 2002) 03 METHODOLOGY OF THE STUDY __ PAGE 10 04 CORPORATE CITIZENSHIP OF DAX 30 COMPANIES __ PAGE 13 The world is facing dramatic challenges ranging from social people from both the for-profit and non-profit sectors still INTEGRATED CORPORATE CITIZENSHIP: inequality and climate change to healthcare systems that argue that companies should focus on their business and 05 SCHNEIDER ELECTRIC are stretched to the limit. Recognizing these challenges, limit their social activities to paying taxes and simply making the United Nations with their Sustainable Development donations to Non-Governmental Organizations (NGOs). __ AS GOOD PRACTICE EXAMPLE PAGE 20 Goals (SDGs) are calling upon all members of society to play their part. However, this view is slowly changing in different parts of the world, with new regulations being put in place to encourage With their expertise and resources, companies can play a key and enforce a more active role of companies in addressing __ SUMMARY AND RECOMMENDATIONS PAGE 21 role in addressing these societal challenges: the fact that the societal changes.